FDA announces immediate market withdrawal of Zantac/ranitidine medications
The Food and Drug Administration today it is requesting manufacturers immediately withdraw all prescription and over-the-counter ranitidine drugs (commonly known by the brand name Zantac) from the market.
This is the latest step in an ongoing investigation of the carcinogenic contaminant N-Nitrosodimethylamine (NDMA), which in some ranitidine products increases over time and when stored at higher than room temperatures to unacceptable levels.
The FDA advised consumers taking OTC ranitidine to stop taking any tablets or liquid they currently have, dispose of them properly and not buy more; patients taking prescription ranitidine should speak with their health care professional about other treatment options before stopping the medicine.
Related News Articles
Headline
The U.S. has had 935 confirmed cases of measles so far this year, according to the latest data from the Centers for Disease Control and Prevention. Cases have…
Headline
The Food and Drug Administration published a notice from Amneal Pharmaceutical that said the company is recalling two lots of its Ropivacaine Hydrochloride…
Headline
The Food and Drug Administration has identified a Class I recall of Q’Apel Medical 072 Aspiration System after the company submitted three device event reports…
Headline
There have been 8,064 reported cases of whooping cough in the U.S. so far this year, according to the latest data from the Centers for Disease Control and…
Headline
A study published April 17 by BMC Infectious Diseases found increased incidents of Acinetobacter baumannii and carbapenem-resistant A. baumannii infections…
Headline
The Food and Drug Administration has issued alerts for issues with certain catheters made by BD and Conavi. BD identified an increase in material fatigue…